CIITA G-286A promoter polymorphism impairs monocytes HLA-DR expression in

- 2 septic shock and is rescued by interferon-γ
- 4 Jordi Miatello^{1,2}, Anne-Claire Lukaszewicz^{3,4}, Valérie Faivre^{5,6}, Stéphane Hua⁷, Kim Zita
- 5 Martinet⁷, Christine Bourgeois⁷, Lluis Quintana-Murci^{8,9}, Didier Payen¹⁰, Michele
- 6 Boniotto^{11*}, Pierre Tissières^{1,2*}
- ¹Institute of Integrative Biology of the Cell, CNRS, CEA, Paris-Saclay University, Gif-sur-
- 9 Yvette, France;

1

3

- ²Paediatric Intensive Care and Neonatal Medicine, AP-HP, of Paris-Saclay University,
- 11 Bicêtre Hospital, Le Kremlin-Bicêtre, France;
- ³EA 7426 PI3 (Pathophysiology of Injury-induced Immunosuppression), Hospices Civils de
- 13 Lyon/ Lyon University/bioMérieux, E. Herriot Hospital, Lyon, France;
- ⁴Department of Anesthesiology and Intensive Care, Hospices Civils de Lyon, Neurological
- 15 Hospital Pierre Wertheimer, Lyon University, Bron, France;
- ⁵Saint-Louis Lariboisière Hospital, AP-HP, Denis Diderot University, Paris, France;
- 17 ⁶INSERM 1160 Denis Diderot University, Paris, France;
- ⁷Paris-Saclay University, INSERM, CEA, Center for Immunology of Viral, Auto-immune,
- 19 Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France;
- ⁸Unit of Human Evolutionary Genetics, CNRS, UMR2000, Institut Pasteur, Paris, France;
- ⁹Chair Human Genomics and Evolution, Collège de France, Paris, France;
- ¹⁰Denis Diderot University, Paris, Sorbonne, Cité Paris, France;
- 23 ¹¹Institut Mondor for Biomedical Research/INSERM U955 Team 16, Paris-Est Créteil
- 24 University, Créteil, France.
- * Both authors contributed equally.

1 **Corresponding authors:** Pierre Tissières, MD, DSc 2 Institute of Integrative Biology of the Cell 3 CNRS, CEA, Paris Saclay University 1 Avenue de la Terrasse 4 5 91190 Gif-sur-Yvette, France 6 Email: pierre.tissieres@i2bc.paris-saclay.fr 7 8 **Statement of equal author contributions:** MB and PT contributed equally. 9 Statement of article series: none. 10 11 12 **Statement of prior presentation:** presented partially in abstract form at the Cell symposia: 13 Human immunity, Lisbon, Portugal, August 2012. 14 15 Manuscript word count: 4277 words

Keypoints

1

6

7

- CIITA G-286A polymorphism reduces promotor activity and significantly impact
- 3 monocyte HLA-DR expression and mortality in septic shock
- Downregulatory effects of CIITA G-286A polymorphism on monocyte HLA-DR
- 5 expression can be reverse by IFN-γ in patients with septic shock

ABSTRACT (245 words)

- 8 Monocyte HLA-DR is an increasingly recognized markers of sepsis-induced
- 9 immunodepression, but its regulatory mechanisms remain poorly understood in sepsis.
- 10 Several evidence for positive selection on the 5' promoter region of HLA class II
- transactivator (CIITA) gene, the master regulator of MHC class II, have been gathered in the
- 12 European population, and its role in sepsis has never been demonstrated, whilst suggested in
- autoimmune disease. We aim to describe the effect of rs3087456 polymorphism, localized on
- 14 CIITA promoter III (pIII), on mortality of patients with septic shock, and investigate the
- 15 mechanisms regulating HLA-DR expression. Genotyping of 203 patients with septic shock
- showed that, in A dominant model, GG genotype was associated with 28-day mortality (OR
- 2.29; 95% CI: 1.01 to 5.22; P = 0.043). Monocyte HLA-DR remained low in patients with GG
- 18 genotype whereas it increases as early as at the end of the first week in intensive care in
- 19 patients with AA or AG genotype. Using site-directed mutagenesis, in vitro reporter gene
- 20 promoter activity of the pIII was decreased in GG genotype in monocyte cell line. Interferon-γ
- 21 (IFN-γ) restored pIII activity in GG genotype as well as restore, in ex vivo experiment in
- healthy volunteers, CIITA pIII expression of GG genotype. Hereby, we demonstrated that
- 23 rs3087456, a positively selected polymorphism of *CIITA* proximal promoter, significantly
- 24 impact monocyte HLA-DR expression in patients with septic shock through CIITA promoter

- 1 activity, that can be rescued using IFN-γ, offering a new perspective in genetic susceptibility
- 2 to sepsis and targeted immunomodulatory therapy.

INTRODUCTION

1

2 Sepsis is a life-threatening condition with more than 19 million cases and 5 million deaths per year worldwide and is recognized as a global priority by the World Health Organization ^{1,2}. 3 Incidence of sepsis has increased during last decades because of advancing age, 4 5 immunodepression and multidrug-resistant infections³. Nevertheless, mortality remains stable 6 pending the prompt administration of antibiotics, the use of fluid resuscitation and vasopressors to reverse hypotension and maintain tissue perfusion⁴. Sepsis is now widely 7 8 recognized as an inappropriate host response to infection with transient or persistent state of 9 immunodepression ^{5,6}. Diagnosis and specific therapies targeting host response, such as antiendotoxin serum or purified anti-endotoxin ⁷, high-dose steroids or inhibitors of the pro-10 inflammatory cytokines IL-1, IL-1 receptor, and TNF- α ⁸⁻¹⁰, anticoagulants ^{11,12} (activated 11 12 protein C) were investigated. Beside strong physiopathologic rationale, most of these studies 13 failed to be beneficial. However, when patients are stratified according to specific 14 immunological phenotypes, these therapies were shown to improve survival, whilst worsening the conditions of others ¹³. 15 16 Sepsis-induced immunodepression is now recognized as being associated with both mortality and emergence of secondary infections ^{14,15}. To assess the patients' immunodepression status, 17 use of HLA-DR expression in circulating monocytes (mHLA-DR) is widely recognized ¹⁶. A 18 19 persistent low level of mHLA-DR measured by flow cytometry is associated with the development of secondary infections and impaired clinical outcome ^{14,15}. Similarly, decreased 20 21 mRNA levels of several genes controlling HLA-DR protein structure, transport and peptide loading have been associated to poor sepsis outcome ^{17–19}. Among these, expression of the 22 23 master regulator of HLA class II, class II transactivator (CIITA), was shown to be reduced in deceased septic patients ¹⁷. MHC class II expression is controlled at the level of transcription 24 25 by a highly conserved regulatory module that is found in the promoters of the gene encoding

1 the α-chain and β-chain of all MHC class II molecules (HLA-DP, -DQ, -DR, HLA-DM and -2 DO). CIITA gene expression is regulated mainly at the level of transcription that is driven by 3 a large regulatory region containing four distinct promoters. Among these four promoters 4 regions, three main CIITA isoforms are produced but their functions are not clear yet. Cell 5 specificity is determined by transcriptional control of the CIITA gene through the differential 6 activity of three of the four promoter regions. Promoter I (pI) is used mainly in dendritic cells 7 and is - induced IFN-γ in macrophages, pIII is activated in B cells and activated T cells, and pIV is induced by IFN-γ in cells that do not express usually the MHC class II ²⁰. 8 9 Mutations of CIITA gene are causing severe haplotype insufficiency, such in bare lymphocytes syndrome, that impairs expression of MHC class II genes ^{21,22}. Among the 10 11 various single nucleotide polymorphism (SNP) described, rs3087456 in the CIITA pIII is associated to a variety of immune-inflammatory disease and cancer ^{23,24}. Swanberg et al ²³ 12 13 showed that rs3087456 influence CIITA and HLA-DR transcripts in human peripheral blood 14 mononuclear cells (PBMCs) stimulated by IFN-γ and demonstrate its association with 15 rheumatoid arthritis, multiple sclerosis, and myocardial infarction in Swedish population. 16 Other association of this SNP with autoimmune diseases such as systemic lupus erythematosus ²⁵, myasthenia gravis ²⁶, celiac disease ²⁷ and primary adrenal insufficiency ²⁸ 17 18 were published. However, this association is debated suggesting that gene-gene, gene-19 environment may interfere. As an example, a first meta-analysis found no significant 20 association between rs3087456 and rheumatoid arthritis, whilst a significant association, 21 further increased in Scandinavian cohorts, was identified in other study suggesting that 22 population genetics may play an important role in rs3087456 associated clinical phenotypes ^{29,30}. Vasseur et al ³¹ provided some evidence of a positive selection of the 5' genomic region 23 24 of CIITA. The positive selection, detected by LD-based tests and Fst tests, identified as highly

- differentiated in Europe (27 % have a G variant, 73 % an A). In addition, SNP rs12596540 is
- shown to be in high linkage disequilibrium ($r^2 > 0.6$) with SNP rs3087456 31 .
- 3 Considering the role of CIITA in the regulation of HLA-DR, and its association with
- 4 immune-inflammatory diseases, we hypothesize that population-selected rs3087456 or its
- 5 linked SNP rs12596540, may impact monocyte HLA-DR expression and sepsis outcome in
- 6 critically septic patient, and evaluate the role of IFN- γ in reversing the phenotype.

MATERIALS AND METHODS

1

25

2 **Study Population and Human Samples** 3 Two hundred and twenty-one DNA samples were obtained from septic shock patients 4 admitted in the Critical Care Unit of the department of Anesthesiology, Lariboisière 5 University Hospital, Paris, France, between February 2004 and November 2005. The study 6 was approved by the Cochin Hospital Ethics Committee (# CCPPRB 2061), Assistance 7 Publique Hôpitaux de Paris. Of the 221 samples, 17 had insufficient amount of DNA for SNP 8 genotyping and one patient had no data for the primary outcome. All patients fulfilled criteria 9 of the American College of Chest Physicians/Society of Critical Care Medicine for septic shock ³². Patients were followed up throughout their ICU stay. Only subjects with clinical and 10 11 biological data available for more than 7 days were analyzed. Clinical and biological 12 characteristics were also collected. These included demographic characteristics (e.g. age, 13 gender), biological data such as measurement of mHLA-DR on a twice weekly base, severity 14 scores (e.g. SAPS II: Simplified Acute Physiology Score II and SOFA: Sequential Organ 15 Failure Assessment), infection foci and complete blood cell count. For ex-vivo and in-vitro 16 experiments, peripheral blood from healthy blood donors were collected at the French 17 national blood collection center (Etablissement Français du Sang, EFS). According to EFS 18 standardized procedures for blood donation, written informed consent was obtained from 19 healthy volunteers. 20 **SNP** Genotyping 21 Genomic DNA (gDNA) was extracted from 200 µL of peripheral whole blood using the 22 NucleoSpin Blood kit (Macherey-Nagel, Düren, Deutschland) following manufacturer's 23 instruction. Genomic DNA concentration was measured (NanoDrop 2000 spectrophotometer, 24 ThermoFisher, Waltham, MA) and quality assessed (260/280 ratio between 1.7-1.9). Presence

of two single nucleotide polymorphisms -286G/A (rs3087456) and -712G/A (rs12596540)

- 1 located on the CIITA promoter III were analyzed. Genotyping was performed blinded to the
- 2 clinical data. SNP genotype was performed using commercially available TaqMan assays
- 3 (Life Technologies, La Jolla, CA). Probe and primer combinations were designed to
- 4 discriminate the two SNPs (Supplemental material, Table 1). Real time allelic discrimination
- 5 assays were performed using SsoFast Probes Supermix (Bio-Rad, Hercules, CA) and a CFX-
- 6 96 real time PCR system (Bio-Rad, Hercules, CA).

Cell isolation and culture

7

- 8 Peripheral blood mononuclear cells from healthy volunteers were isolated by Ficoll density-
- 9 gradient centrifugation. B cells from blood donors were isolated using the MS columns and
- the CD19 Microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany) following
- manufacturer's protocols. Monocytes were isolated by positive selection using MS columns
- and the CD14 Microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany). To assess the
- cell purity by flow cytometry analysis, B cells were stained with fluorescein isothiocyanate
- 14 (FITC)-conjugated anti-CD20 (Miltenyi Biotec, Bergisch Gladbach, Germany), and
- monocytes were labeled with phycoerythrin (PE)-conjugated anti-CD14 (BD Biosciences, Le
- Pont de Claix, France). Isolated cells had an average purity of 90% (\pm 8%) as determined by
- 17 flow cytometry analysis.
- PBMCs were cultured in 24-well plates at 2 x 10⁶ cells/ml in RPMI with 10% FBS at 37°C,
- 19 5% CO₂. Isolated CD14⁺ cells were cultured at 2.5 x 10⁵ in 24-well plates in DMEM with 5%
- FBS at 37°C, 5% CO₂. Isolated CD19⁺ cells were cultured at 10⁵ cells in 96-well plates in
- 21 RPMI 10% FBS at 37°C, 5% CO₂. Cultured cells were incubated in the presence or absence
- of 50 UI/ml of human recombinant IFN-γ (ImmunoTools, Friesoythe, Germany). After 6
- 23 hours, CD14⁺ and CD19⁺ cells were harvested for RNA extraction, whilst after 24 hours,
- 24 PBMCs were collected for FACS analysis.

25 Total RNA isolation and quantitative PCR analysis

1 Total RNA was isolated from monocytes and B cells using the NucleoSpin® RNA XS 2 (Macherey-Nagel, Düren, Deutschland), following manufacturer's instruction. cDNA was 3 generated from 200 ng of total RNA using iScriptTM cDNA Synthesis Kit (Bio-Rad, Hercules, 4 CA). Primers for each CIITA isoform and for the large subunit of ribosomal protein 5 (RPLPO), were designed using the software Beacon Designer 7.0 (PREMIER Biosoft, Palo 6 Alto, CA) and are reported in together with working concentrations and amplification efficiencies (Supplemental material, Table 1). RPLPO was used as a reference gene and the 7 relative quantity of the transcript was calculated by the $2^{-\Delta\Delta Ct}$ method ³³. PCR reactions were 8 9 performed in a CFX96 real time PCR system (Bio-Rad Hercules, CA) using the SsoFast 10 EvaGreen Supermix (Bio-Rad, Hercules, CA). 11 Flow cytometry analysis For septic patients, mHLA-DR analysis was described elsewhere ³⁴. Shortly, peripheral blood 12 13 was sampled in EDTA anticoagulants tubes at different time points (day 1, 2, 7, 14, 21 and 14 28) following admission. Quantification of mHLA-DR on circulating monocytes was performed using a standardized flow cytometry assay as previously described ^{34,35}. To 15 16 quantify, the median fluorescence intensity of the entire monocyte population was then 17 transformed to number of antibodies per cell (AB/C) using calibrated PE beads (BD 18 QuantiBRITETM PE BEADS, Becton-Dickinson San Jose, CA). 19 For analysis of healthy donors' blood, isolated peripheral blood mononuclear cells (PBMCs), 20 monocytes and B cells were washed once in PBS. After being washed once in cold PBS, cells 21 were incubated at 4°C for 15' with the Human Fc Receptor Binding Inhibitor (eBioscience, 22 San Diego, CA) to avoid unspecific binding of labeled antibodies. Cells were then incubated 23 with fluorescently labeled antibodies were added for 15 min at 4°C. The antibodies mix 24 contained: Fluorescein isothiocyanate (FITC)-conjugated anti-CD20 (mouse monoclonal 25 IgG1κ, clone LT20, Miltenyi Biotec, Bergisch Gladbach, Germany), phycoerythrin (PE)-

1 conjugated anti-CD14 (mouse monoclonal IgG2α,κ, clone M5E2, BD Biosciences, Franklin 2 Lakes NJ) and PE-cyanine 7 (PE-Cy7)-conjugated anti-HLADR (mouse monoclonal IgG2α,κ, 3 clone G46-6, BD Biosciences, Franklin Lakes, NJ). After two PBS washes, cells were 4 suspended in 1% paraformaldehyde. Flow cytometry was performed on a BD FACSCanto 5 (BD Biosciences, Franklin Lakes, NJ) and results analyzed by the software FlowJo (TreeStar 6 Inc, Ashland, OR). 7 **Cell culture and Transfection** 8 Human leukemic monocyte lymphoma cell line U937 and human Burkitt's lymphoma cells 9 (Raji) were cultured in RPMI 1640 containing 10% heat-inactivated foetal bovine serum 10 (FBS), 1.0 mM sodium pyruvate, amino acids, 20 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin at 37°C in 5% CO₂. 4 x 10⁵ cells were transfected with 1 µg of reporter 11 12 plasmid and 10 ng of pRL Renilla luciferase vector (Promega, Madison, WI) using 13 TurbofectTM Transfection Reagent (Thermo Fisher Scientific, Fermentas, Waltham, MA). 14 After transfection, the cells were incubated for 30 hours and stimulated by 50 UI/ml rIFN-y 15 (ImmunoTools, Friesoythe, Germany) for 6h or left untreated. 16 Plasmid and Dual-Luciferase Reporter assays 17 The 1200 bp of the type III promoter of MHCIITA was cloned in pGL-3 firefly luciferase 18 reporter vector (Promega, Madison, WI). Single-nucleotide polymorphisms G-286A 19 (rs3087456) and G-712A (rs12596540) were inserted by using site-specific mutagenesis 20 following published protocols. All the inserts were verified by Sanger sequencing. Dual-21 Luciferase assay was performed with the Dual-Glo luciferase Assay (Promega, Madison, WI), 22 following manufacturer's instructions. Firefly and Renilla luciferase substrates fluorescence 23 was recorded by a TriStar LB 941 (Berthold Technologies, Wilbad, Germany). As an internal 24 control, pRL-TK, expressing the Renilla luciferase under the control of the constitutive TK 25 promoter was co-transfected (Promega, Madison, WI). Results are represented by the mean

- value and the standard deviation and are expressed as relative luciferase activity (ratio of
- 2 firefly luciferase activity to renilla luciferase activity). To confirm the results, experiments
- 3 were performed in triplicates and each one was carried out three times.

4 Statistical analysis

- 5 Allele and genotype frequencies were calculated by direct counting. Hardy-Weinberg
- 6 equilibrium for the two SNPs was assessed by the software Arlequin v3.11. Analysis of
- 7 association between genotype and binomial clinical outcomes using different genetic models
- 8 was performed by using the software plink (http://pngu.mgh.harvard.edu/~purcell/plink/).
- 9 Results are presented as range and median for continuous variables and as proportion of total
- 10 for categorical variables. Differences in HLA-DR, SOFA and SAPS II scores for the different
- 11 genotypes were analyzed by using the Kruskal-Wallis test run in STATA software. The
- Wilcoxon rank sum test was applied to analyze continuous variables between different
- 13 genotypes. Mann-Whitney Test was applied for analysis of luciferase experiments by using
- the software GraphPad Prism 8.0. *P* values < 0.05 were considered significant.

RESULTS

1

2

25

3 Severity and mortality in septic shock in association to CIITA rs12596540 and rs3087456 4 genotypes 5 Two hundred and three patients with septic shock were included in the analysis. The main 6 patient characteristics are shown in Table 1. Allele frequency and genotype distribution were similar to that observed by Vasseur et al ³¹: rs3087456: AA 45%, AG 41%, GG 13%; 7 8 rs12596540: AA 56%, AG 37%, GG 7%. Most cell counts were not significantly different 9 between genotypes, but patients who had the CIITA rs12596540 GG genotype had a higher 10 lymphocyte count. Both polymorphisms met the Hardy Weinberg law in our cohort. To 11 determine whether CIITA rs12596540 and rs3087456 SNPs were associated with severity and 12 mortality in septic shock, genotype frequencies were determined. As reported in Table 1, no 13 significant association was found for both SNPs with clinical severity scores (SAPS II and 14 SOFA scores at day 1). As given in Table 2, we observed a trend of increasing mortality in 15 patients with GG genotype for both SNPs. In an A-dominant model, patients homozygous for 16 allele CIITA rs3087456 GG genotype had a significant increased risk of 28-day mortality 17 (55.6% for GG genotype vs. 35.2% for AA and AG genotypes, OR: 2.298, CI 95% [1.013-18 5.217], P = 0.043) (Table 2). The presence of rs3087456*A allele was associated with a 19 decreased risk of death from septic shock. We noted that there was a non-significant trend 20 towards an increase in 7-day mortality for GG genotype for rs12596540 (AA or AG: 25.9% 21 vs. GG: 50%, OR: 2.857, CI 95% [0.954-8,558], P = 0.05). No association was found for 22 secondary infections between the different genotypes of CIITA promoter III gene in both 23 SNPs (Table 2Error! Reference source not found.). We further evaluate the impact of both 24 SNPs on mHLA-DR expression in septic shock patients.

CIITA rs12596540 and rs3087456 genotypes and mHLA-DR surface expression

- 2 In septic shock patients, circulating mHLA-DR expression was measured at different time
- 3 point during the ICU stay. For the rest of the analysis, due to the mortality data suggesting an
- 4 effect only in an A-dominant model, we considered only this later model. For rs12596540 and
- 5 rs3087456, septic patients with AA or AG genotype showed a significant early increase in
- 6 mHLA-DR level, whereas patients with GG genotype displayed a persistent low mHLA-DR
- values (Wilcoxon signed rank test, P < 0.03 vs. basal) (Figure 1Error! Reference source not
- 8 **found.**).

1

- 9 To investigate the role of CIITA polymorphisms in healthy individuals, we measured basal
- 10 mHLA-DR expression in 50 controls and evaluate its response to IFN- $\square ex$ -vivo stimulation.
- 11 There was no difference between different genotypes in both polymorphisms (rs3087456: AA
- or AG = 1371 [95%CI, 1154 to 1625] MFI vs. GG = 1192 [95% CI, 864 to 2207] MFI, P =
- 13 0.87; rs12596540: AA or AG = 1374 [95%CI, 1154 to 1642] MFI vs. GG = 1137 [95%CI,
- 14 864 to 1889] MFI, P = 0.45; Figure 2). Following IFN- γ stimulation, mHLA-DR significantly
- increased in monocytes of healthy volunteers with AA or AG genotype (rs3087456: 1455 vs.
- 3569 MFI [CI 95%, 1572 to 2656], *P* < 0.0001; rs12596540: 1471 vs. 3518 MFI [CI 95%,
- 17 1506 to 2587], P < 0.0001; Figure 2). For rs3087456, mHLA-DR was significantly lower for
- 18 GG genotype after stimulation with IFN- γ (AA or AG = 3919 [95% CI, 2912 to 4434] MFI vs.
- 19 GG = 1898 [95% CI, 1284 to 2835] MFI, P < 0.05, Figure 2). In healthy volunteers, a
- 20 homozygous GG status did not allow such a high response to IFN-γ. As with mortality data,
- 21 we did not observe significant difference in mHLA-DR expression with rs12596540
- 22 genotypes and focused the rest of the analysis on rs3087456 genotype. To evaluate the effect
- 23 of rs3087456 on CIITA expression regulation, we tested its specific activity on pIII on
- 24 different leukemoid cell lines.

1 Promoter activity of A/G at position -286 (rs3087456) in the type III promoter of CIITA 2 Functional consequence of this polymorphism on pIII activity was evaluated using reporter 3 gene assays. To understand the mechanism by which CIITA gene transcripts are expressed, 4 dual luciferase reporter assays were used to detect specific CIITA promoter activity. After 5 transfection into a monocyte-like cell line (U937), G-286A*rs3087456 pIII activity 6 significantly decreased compared with the activity of wild-type (WT) construct (P < 0.001) 7 (Figure 3). After stimulation by IFN-γ, activity of G-286A*rs3087456 pIII recovered a similar 8 activity than WT promoter (P < 0.001) (Figure 3). As isoforms of pIII are specifics of B and 9 activated-T cells, we transfected B lymphocyte-like cell line (Raji) and T lymphocyte-like cell 10 line (Jurkat T). In B cells, luciferase activity of G-286A*rs3087456 pIII significantly 11 decreased compared with WT (P < 0.05), and IFN- γ did not restore activity of mutated pIII (P12 = 0.23) (Figure 3). For T cells, activity of G-286A*rs3087456 pIII failed to show any 13 difference compared to WT promoter both on basal and IFN-γ stimulated condition (Figure 14 3). These results confirmed that CIITA pIII activity is involved in the decrease of mHLA-DR 15 expression in homozygote GG healthy volunteers. To prove the transcriptional effect of G-16 286A*rs3087456 pIII on *CIITA* expression, we quantified pIII related transcripts. 17 18 Rs3087456 genotype effect on CIITA isoforms expression 19 To determine whether the CIITA rs3087456 polymorphism was associated with different 20 expression of CIITA isoforms derived from the promoter pIII and pIV, mRNA of purified 21 monocytes (CD14⁺) and B cells (CD19⁺) was quantified by Q-PCR. mRNA encoding CIITA 22 pI isoform was not recovered in isolated monocytes and B cells from healthy donors (data not 23 shown). In monocytes, no difference in basal expression level of pIII (P = 0.18) and pIV (P =24 0.24) transcripts between AA or AG and GG genotypes (Figure 4). After 6 hours of ex-vivo 25 cells stimulation with IFN- γ , pIII and pIV transcripts were significantly up-regulated (P <

- 1 0.0001, Figure 4) in monocytes for AA or AG as well as GG genotype (Figure 4). In B cells,
- 2 no difference was observed in pIII or pIV transcripts expression in unstimulated cells.
- 3 Following IFN-γ stimulation, only AA or AG genotype pIV transcripts expression
- 4 significantly increased (P < 0.05, Figure 4). However, pIV transcripts induction following
- 5 IFN-γ stimulation was much higher in monocytes (45 fold increase: from 1.46 [CI 95%, 0.59
- 6 to 2.28] to 66.98 [CI 95%, 38.32 to 164.6]) than in B cells (2 fold increase, from 4.40 [CI
- 7 95%, 2.37 to 8.27] to 8.70 (CI 95%, 4.42-12.05]) (Figure 4). Altogether rs3087456
- 8 polymorphism was not impacting CIITA isoforms basal expression, but is similarly inducible
- 9 by IFN-γ in both AA or AG and GG in monocytes but not in B cells.

DISCUSSION

1

25

2 In this study, we showed that G-286A CIITA promoter polymorphism is associated with an 3 increase 28-day mortality in septic shock and altered mHLA-DR kinetics. Monocyte HLA-4 DR impaired expression is related to an altered response to IFN-γ stimulation in G-286A. This 5 regulatory effect seems to be related to altered basal pIII activity that is restored in G-286A 6 after IFN-γ stimulation. 7 8 Gene polymorphisms is widely recognized as important determinants of host response to pathogens and infections have been a strong selective sieve of human genome evolution ^{36,37}. 9 10 In this respect, multiple human gene polymorphisms, positively selected in the population, are associated with survival during infection ^{38,39}. For example, premature stop codon inactivating 11 12 the caspase-12 gene has been suggested to provide a selective advantage through sepsis resistance in population that experience more infectious diseases ⁴⁰. Nevertheless, different 13 14 studies supported the idea that allele selected to resist to human pathogens, may play a role in 15 autoimmune disease susceptibility 41. Recently, Vasseur et al 31 identified one selected SNP of 16 CIITA promoter region, rs3087456, which is positively selected in humans and known to be 17 associated with autoimmunity, and therefore may prove to be a strong candidate SNP in 18 sepsis resistance. In our study, rs3087456 is associated with improved survival to septic shock confirming its potential selective function. In addition to Swanberg et al ²³ showing that 19 20 rs3087456 is correlated with MHC class II transcripts, we showed its correlation with 21 expression of HLA-DR on the cell membrane of monocytes in patients with septic shock. In 22 homozygous GG patients, our data showed that mHLA-DR remained low throughout the ICU 23 stay, suggesting that persistent sepsis-induced immunodepression may be partially related to 24 this polymorphism.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

The effect of the rs3087456 polymorphism on the regulation of HLA-DR expression has not been previously studied. To our knowledge, this is the first study to investigate the regulatory effects of this promoter polymorphism. Our results suggest that GG genotype alters pIII activity in monocytes and B cells but not in T cells, in a cell-type specific manner. Unexpectedly, on basal condition (e.g. monocytes and B lymphocytes from healthy volunteers), pIII related transcripts induction is not significantly different between all haplotypes. Following ex vivo stimulation with IFN-γ, pIII transcripts expression was increased only in monocytes. Similarly, pIV transcripts expression is not different in the basal condition, but expression increases after IFN-γ only in monocytes. These suggest that, in basal condition (e.g. healthy), transcriptional induction counteracts altered promoter activity of GG or repressor inhibit transcription in AA or AG haplotypes, both hypotheses encompassing complex transcription regulatory mechanisms. Few CIITA transcriptional regulatory mechanisms are described. Recently, immuneenhancing CpG and non-CpG oligodeoxynucleotides (ODNs) have been described as having a role in regulating expression of MHC class II and costimulatory molecules. Wang et al ⁴² showed that non-CpG ODNs (rODNs) down-regulate HLA-DR expression in monocytes and block promoter III-directed transcription of CIITA in these cells. The precise inhibitory molecular effects of rODN on pIII activity are not understood, and more specifically, its precise promoter interaction not studied. Lohsen et al ⁴³ described a distal regulatory elements, known as hypersensitive site 1 - HSS1 (located ~3kb upstream of pI) with PU.1, NF-κB, and Sp1 interacting with pIII through a looping interaction. Interestingly, proximal regulatory elements were described, and include inducers (e.g. AP-1, Sp1, CREB, NF-Y, ARE-1, ARE-2), and repressors (eg. PRDI-BF1/BLIMP-1, ZBTB32). Other mechanisms are involved in CIITA expression regulation. Among these, in B cells, restricted access of pI due

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

to extensive DNA methylation induces a switch to pIII activation ⁴³. The -300 region of CIITA has been well identified as an important proximal regulatory regions ⁴⁴. It is plausible that pIII rs3087456 polymorphism may interfere with transcription in monocyte during sepsis and CIITA expression be rescued through IFN-γ stimulation. Whether this may be directly related to a cis- or trans- regulatory mechanism is unknown. Ni et al 45 identified a dependent distal enhancer regulating IFN-γ-induce expression of CIITA through pIV. This IFN-γ induce promoter activation is dependent on BRG1, an ATP-dependent remodeling factor, which promotes the formation of a dynamic three-dimensional chromatin loop and demonstrates the importance of distant enhancer/silencer regions in CIITA expression regulation. In our study we showed that expression in monocyte of pIV isoforms following IFN-γ is ~2.7 fold higher than pIII, which confirms the preferential activation of pIV after IFN-γ induction. Altogether, these facts support the evidence that IFN-γ is a preferential inducer of CIITA expression that may overcome monocytic MHC class II phenotype triggered by rs3087456 polymorphism in septic patients. The detailed transcriptional mechanism is unknown but the complexity of the regulation of CIITA expression renders difficult the precise determination out of highthroughput promoter analysis. Another observation of this study is the relation between *CIITA* promoter III SNP and mortality in septic shock. Outside the indirect relation between CIITA expression and mortality through mHLA-DR expression ^{17,46,47}, there is increasing descriptions of the direct role of CIITA in regulating various effectors encountered during sepsis. CIITA has been shown to regulate the expression of several immune related genes such as interleukin (IL)-4, collagen α2, Fas ligand, and plexin A1. As an illustration, Nozell et al ⁴⁸ showed that CIITA was able to inhibit MMP-9 expression, a matrix metalloproteinase involved in the degradation of extracellular matrix in lung injury. Interestingly, the inhibition of MMP-9 in a sepsis rat

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

model with induced lung injury resulted in an increase survival ⁴⁹. Hereby, we show that IFNy was able, in rs3087456 GG genotype, to restore CIITA promoter activity, CIITA pIII and pIV expression as well as HLA-DR expression in monocyte, suggesting that IFN-γ may be a suitable immunomodulatory therapy to recover MHC class II expression. In the seminal article by Döcke et al ⁵⁰, authors showed that IFN-y was able to restore monocyte functions in 8 patients with sepsis. More recently, in a cohort of 20 paediatrics and adults' patients with sepsis, we showed that immunotherapy with IFN-γ was safe to improve the immune host defense, particularly the monocyte HLD-DR expression in patients with prolonged downregulation of mHLA-DR, and was associated with a very high survival rate ⁵¹. However, Leentjens et al ⁵² suggested in healthy volunteers with LPS-induced immunoparalysis that the modulatory effect of IFN-γ is variable, despite the significant increase in mHLA-DR expression. Interestingly, GM-CSF did not induce a significant increase in mHLA-DR in this study ⁵². This is in agreement with the study of Hornell et al ⁵³ showing that GM-CSF increase CIITA type I and III transcript expression but not of type IV. The use of mHLA-DR to assess the risk of secondary infection after septic shock is well admitted ^{14,15}. The use of a threshold of 8,000 AB/C to define a reduction in mHLA-DR expression to diagnose an acquired immunosupression gets more credence, in particular if it is lasting after day 3 post admission ^{51,54}. Hereby, we showed that rs3087456 GG genotype was significantly associated with unresolving low mHLA-DR kinetics, predicting a persistent immunodepression phenotype in patients with septic shock. This study opens two important perspectives: First, a genetic susceptibility affecting MHC class II master regulator CIITA is shown to be associated with defective mHLA-DR expression in patients with septic shock and dismal outcome. This allows to anticipate the development of sepsis-induced immunodepression. Second, the demonstration of IFN-y effect

- 1 to rescue the functional consequence of this genotype, suggest the use of this genetic
- 2 biomarker to identify patients who may benefit of IFN-γ-based immunomodulatory therapy.
- 3 In conclusion, we report that CIITA rs3087456 GG genotype is associated with impaired m-
- 4 HLA-DR expression in septic shock, predictive of development of persistent
- 5 immunodepression, and demonstrate the effect of IFN-γ to rescue altered MHC class II
- 6 expression.

REFERENCES

- 2 1. Reinhart, K. et al. Recognizing Sepsis as a Global Health Priority A WHO Resolution.
- 3 N. Engl. J. Med. 377, 414–417 (2017).
- 4 2. Fleischmann, C. et al. Assessment of Global Incidence and Mortality of Hospital-treated
- 5 Sepsis. Current Estimates and Limitations. *Am. J. Respir. Crit. Care Med.* 193, 259–272
- 6 (2016).
- 7 3. Kumar, G. *et al.* Nationwide trends of severe sepsis in the 21st century (2000-2007).
- 8 *Chest* 140, 1223–1231 (2011).
- 9 4. Rhodes, A. et al. Surviving Sepsis Campaign: International Guidelines for Management
- of Sepsis and Septic Shock: 2016. *Intensive Care Med.* 43, 304–377 (2017).
- 5. Singer, M. et al. The Third International Consensus Definitions for Sepsis and Septic
- 12 Shock (Sepsis-3). *JAMA* 315, 801–810 (2016).
- 6. Hotchkiss, R. S., Monneret, G. & Payen, D. Sepsis-induced immunosuppression: from
- 14 cellular dysfunctions to immunotherapy. *Nat. Rev. Immunol.* 13, 862–874 (2013).
- 15 7. Ziegler, E. J. et al. Treatment of gram-negative bacteremia and shock with human
- antiserum to a mutant Escherichia coli. *N Engl J Med* 307, 1225–30 (1982).
- 17 8. Eichacker, P. Q. et al. Risk and the efficacy of antiinflammatory agents: retrospective and
- 18 confirmatory studies of sepsis. Am J Respir Crit Care Med 166, 1197–205 (2002).
- 9. Minneci, P. C., Deans, K. J., Eichacker, P. Q. & Natanson, C. The effects of steroids
- during sepsis depend on dose and severity of illness: an updated meta-analysis. *Clin*
- 21 *Microbiol Infect* 15, 308–18 (2009).
- 22 10. Shakoory, B. et al. Interleukin-1 Receptor Blockade Is Associated With Reduced
- 23 Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome:
- Reanalysis of a Prior Phase III Trial. *Crit. Care Med.* 44, 275–281 (2016).

- 1 11. Abraham, E. et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk
- of death. *N Engl J Med* 353, 1332–41 (2005).
- 3 12. Warren, H. S., Suffredini, A. F., Eichacker, P. Q. & Munford, R. S. Risks and benefits of
- 4 activated protein C treatment for severe sepsis. *N Engl J Med* 347, 1027–30 (2002).
- 5 13. Suffredini, A. F. & Munford, R. S. Novel therapies for septic shock over the past 4
- 6 decades. *Jama* 306, 194–9 (2011).
- 7 14. Lukaszewicz, A. C., Faivre, V. & Payen, D. Is monocyte HLA-DR expression monitoring
- 8 a useful tool to predict the risk of secondary infection? *Minerva Anestesiol* 76, 737–43
- 9 (2010).
- 10 15. Wu, J. F. et al. Changes of monocyte human leukocyte antigen-DR expression as a
- 11 reliable predictor of mortality in severe sepsis. Crit Care 15, R220 (2011).
- 12 16. Monneret, G., Lepape, A. & Venet, F. A dynamic view of mHLA-DR expression in
- management of severe septic patients. Crit. Care Lond. Engl. 15, 198 (2011).
- 14 17. Pachot, A. et al. Messenger RNA expression of major histocompatibility complex class II
- 15 genes in whole blood from septic shock patients. Crit Care Med 33, 31–8; discussion 236-
- 16 7 (2005).
- 17 18. Cajander, S. et al. Quantitative Real-Time Polymerase Chain Reaction Measurement of
- 18 HLA-DRA Gene Expression in Whole Blood Is Highly Reproducible and Shows Changes
- 19 That Reflect Dynamic Shifts in Monocyte Surface HLA-DR Expression during the
- 20 Course of Sepsis. *PLOS ONE* 11, e0154690 (2016).
- 21 19. Peronnet, E. et al. Association between mRNA expression of CD74 and IL10 and risk of
- ICU-acquired infections: a multicenter cohort study. *Intensive Care Med.* 43, 1013–1020
- 23 (2017).
- 20. Reith, W., LeibundGut-Landmann, S. & Waldburger, J. M. Regulation of MHC class II
- gene expression by the class II transactivator. *Nat Rev Immunol* 5, 793–806 (2005).

- 1 21. Mach, B., Steimle, V. & Reith, W. MHC class II-deficient combined immunodeficiency:
- a disease of gene regulation. *Immunol Rev* 138, 207–21 (1994).
- 3 22. Steimle, V., Otten, L. A., Zufferey, M. & Mach, B. Complementation cloning of an MHC
- 4 class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte
- 5 syndrome). 1993. *J Immunol* 178, 6677–88 (2007).
- 6 23. Swanberg, M. et al. MHC2TA is associated with differential MHC molecule expression
- 7 and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction.
- 8 *Nat Genet* 37, 486–94 (2005).
- 9 24. Xue, Y. et al. Link between CIITA rs3087456 polymorphism and the risk of laryngeal
- squamous cell carcinoma in a Chinese population. *Pathol. Res. Pract.* 216, 152793
- 11 (2020).
- 12 25. Bronson, P. G. et al. The rs4774 CIITA missense variant is associated with risk of
- 13 systemic lupus erythematosus. *Genes Immun* 12, 667–71 (2011).
- 14 26. Ramanujam, R., Zhao, Y., Pirskanen, R. & Hammarström, L. Lack of association of the
- 15 CIITA -168A→G promoter SNP with myasthenia gravis and its role in autoimmunity.
- 16 *BMC Med. Genet.* 11, 147 (2010).
- 17 27. Dema, B. et al. Autoimmune disease association signals in CIITA and KIAA0350 are not
- involved in celiac disease susceptibility. *Tissue Antigens* 73, 326–329 (2009).
- 19 28. Skinningsrud, B. et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated
- with primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 93, 3310–3317 (2008).
- 29. Bronson, P. G., Criswell, L. A. & Barcellos, L. F. The MHC2TA -168A/G polymorphism
- and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls
- reveals no evidence for association. *Ann Rheum Dis* 67, 933–6 (2008).
- 30. Eike, M. C. et al. CIITA gene variants are associated with rheumatoid arthritis in
- 25 Scandinavian populations. *Genes Immun* 13, 431–6 (2012).

- 1 31. Vasseur, E. *et al.* The evolutionary landscape of cytosolic microbial sensors in humans.
- 2 *Am J Hum Genet* 91, 27–37 (2012).
- 3 32. Levy, M. M. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions
- 4 Conference. *Crit Care Med* 31, 1250–6 (2003).
- 5 33. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time
- 6 quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif 25,
- 7 402–408 (2001).
- 8 34. Lukaszewicz, A. C. *et al.* Monocytic HLA-DR expression in intensive care patients:
- 9 interest for prognosis and secondary infection prediction. *Crit Care Med* 37, 2746–52
- 10 (2009).
- 11 35. Demaret, J. et al. Inter-laboratory assessment of flow cytometric monocyte HLA-DR
- 12 expression in clinical samples. Cytometry B Clin. Cytom. 84B, 59–62 (2013).
- 13 36. Quintana-Murci, L., Alcaïs, A., Abel, L. & Casanova, J.-L. Immunology in natura □:
- clinical, epidemiological and evolutionary genetics of infectious diseases. *Nat. Immunol.*
- 15 8, 1165–1171 (2007).
- 16 37. Casanova, J.-L. & Abel, L. The human genetic determinism of life-threatening infectious
- diseases: genetic heterogeneity and physiological homogeneity? *Hum. Genet.* 139, 681–
- 18 694 (2020).
- 19 38. Deschamps, M. et al. Genomic Signatures of Selective Pressures and Introgression from
- Archaic Hominins at Human Innate Immunity Genes. Am. J. Hum. Genet. 98, 5–21
- 21 (2016).
- 22 39. Quintana-Murci, L. Human Immunology through the Lens of Evolutionary Genetics. Cell
- 23 177, 184–199 (2019).
- 40. Xue, Y. et al. Spread of an inactive form of caspase-12 in humans is due to recent positive
- 25 selection. *Am J Hum Genet* 78, 659–70 (2006).

- 1 41. Barreiro, L. B. & Quintana-Murci, L. From evolutionary genetics to human immunology:
- 2 how selection shapes host defence genes. *Nat Rev Genet* 11, 17–30 (2010).
- 3 42. Wang, J., Roderiquez, G., Jones, T., McPhie, P. & Norcross, M. A. Control of in vitro
- 4 immune responses by regulatory oligodeoxynucleotides through inhibition of pIII
- 5 promoter directed expression of MHC class II transactivator in human primary
- 6 monocytes. J. Immunol. Baltim. Md 1950 179, 45–52 (2007).
- 7 43. Lohsen, S. et al. Common distal elements orchestrate CIITA isoform-specific expression
- 8 in multiple cell types. *Genes Immun.* 15, 543–555 (2014).
- 9 44. Ghosh, N. et al. A Novel Element and a TEF-2-like Element Activate the Major
- Histocompatibility Complex Class II Transactivator in B-lymphocytes. J. Biol. Chem.
- 274, 32342–32350 (1999).
- 12 45. Ni, Z., Abou El Hassan, M., Xu, Z., Yu, T. & Bremner, R. The chromatin-remodeling
- enzyme BRG1 coordinates CIITA induction through many interdependent distal
- enhancers. *Nat Immunol* 9, 785–93 (2008).
- 15 46. Cazalis, M.-A. et al. Decreased HLA-DR antigen-associated invariant chain (CD74)
- mRNA expression predicts mortality after septic shock. Crit. Care 17, R287 (2013).
- 17 47. Turrel-Davin, F. et al. mRNA-based approach to monitor recombinant gamma-interferon
- 18 restoration of LPS-induced endotoxin tolerance. Crit. Care 15, R252 (2011).
- 19 48. Nozell, S., Ma, Z., Wilson, C., Shah, R. & Benveniste, E. N. Class II major
- 20 histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9
- 21 gene expression. *J Biol Chem* 279, 38577–89 (2004).
- 49. Steinberg, J. et al. Metalloproteinase inhibition reduces lung injury and improves survival
- after cecal ligation and puncture in rats. J Surg Res 111, 185–95 (2003).
- 50. Döcke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-gamma
- 25 treatment. *Nat. Med.* 3, 678–681 (1997).

- 1 51. Payen, D. et al. Multicentric experience with interferon gamma therapy in sepsis induced
- immunosuppression. A case series. *BMC Infect. Dis.* 19, 931 (2019).
- 3 52. Leentjens, J. et al. Reversal of immunoparalysis in humans in vivo: a double-blind,
- 4 placebo-controlled, randomized pilot study. Am. J. Respir. Crit. Care Med. 186, 838–845
- 5 (2012).

- 6 53. Hornell, T. M. C., Beresford, G. W., Bushey, A., Boss, J. M. & Mellins, E. D. Regulation
- of the class II MHC pathway in primary human monocytes by granulocyte-macrophage
- 8 colony-stimulating factor. *J. Immunol. Baltim. Md* 1950 171, 2374–2383 (2003).
- 9 54. Monneret, G. et al. Persisting low monocyte human leukocyte antigen-DR expression
- predicts mortality in septic shock. *Intensive Care Med.* 32, 1175–1183 (2006).

Acknowledgments

1

5

- 2 We thank Sergio Crovella (Department of Advanced Diagnostics, Institute for Maternal and
- 3 Child Health-IRCCS 'Burlo Garofolo', Trieste, Italy and Department of Medical, Surgical and
- 4 Health Sciences, University of Trieste, Trieste, Italy) for help with paper revisions.
- 6 **Disclosure**: All authors declare having no financial interest related to the study
- 7 Contribution:
- 8 ACL, DP enrolled the patients and collected clinical data
- 9 JM, MB, SH, KM, CB, VF performed experiments;
- 10 JM, MB, PT analyzed results and made the figures;
- 11 JM, MB, PT, DP, ACL designed the research;
- 12 JM, PT, MB wrote the paper;
- 13 All authors critically reviewed the manuscript.
- 15 **Correspondence**: Pierre Tissières, MD, DSc, Institute of Integrative Biology of the Cell.
- 16 CNRS-CEA-Paris-Saclay University, 1, Avenue de la Terrasse, 91190 Gif-sur-Yvette,
- 17 France; e-mail: pierre.tissieres@i2bc.paris-saclay.fr

Tables legends

1

2

- 3 Table 1. Baseline characteristics of patients in septic shock.
- 4 SAPS II: Simplified Acute Physiology Score II; SOFA = Sequential Organ Failure
- 5 Assessment. Data are median (interquartile range) for continuous variable. * P values were
- 6 calculated with the use of chi-square test and Kruskal-Wallis test.
- 8 Table 2. Genotyped related mortality.
- 9 * P values were calculated with the use of chi-square test and Kruskal-Wallis test.

Figures legends

1

2

9

14

- 3 Figure 1. Monocyte HLA-DR expression in 203 patients with septic shock.
- 4 Circulating monocyte HLA-DR expression is expressed as number of antibodies bound per
- 5 cell (AB/C) as defined using calibrated PE beads (BD QuantiBRITETM PE BEADS, Becton-
- 6 Dickinson San Jose, CA). Results are presented as median with 95% CI and by genotype of
- 7 CIITA rs 12596540 and rs 3087456 in a dominant model. * P < 0.03 vs. basal (Wilcoxon
- 8 signed rank test).
- 10 Figure 2. HLA-DR expression in PBMCs of healthy volunteers.
- 11 Mean fluorescence intensity (MFI) are presented as median with 95% CI and by genotype of
- 12 CIITA rs12596540 and rs3087456 in a dominant model. P values were calculated using
- 13 Mann-Whitney Test. * P < 0.05.
- 15 Figure 3. Transient transfection of U937, Raji and Jurkat T cells with CIITA-promoter-
- 16 luciferase plasmid.
- 17 Transfected cells were stimulated during 6h with IFN-γ. CIITA promoter III activity is
- 18 represented by luciferase activity over empty vector. WT = Wild Type. P values were
- 19 calculated using Mann-Whitney Test. *** P < 0.001 and * P < 0.05.
- 21 Figure 4. mRNA levels for promoter III (pIII) and promoter IV (pIV) isoforms.
- mRNA level in CD14⁺ (monocytes) and CD19⁺ (lymphocytes) from healthy volunteers. Cells
- were stimulated or not by IFN-y during 6h before qPCR. Results are presented as median fold
- 24 change relative to an AA subject normalized to HuRPLPO, and by genotype of CIITA
- 25 rs3087456 in an A-dominant model. P values were calculated using Mann-Whitney Test.
- 26 **** P < 0.0001, *** P < 0.001 and * P < 0.05.

Figure 1.




Figure 2.




Figure 3.





Figure 4.



Tables

Table 1.

| | | G-712 | A (rs12596 | 540) | G-286A (rs3087456) | | | | | |
|--|------------------|--------------------|--------------------|--------------------|--------------------|-------------------|--------------------|-------------------|--------------------|--------------|
| | AA (n = 113) | AG (n = 76) | GG (n = 14) | All (n = 203) | P Value * | AA (n = 92) | AG (n = 84) | GG (n = 27) | All (n = 203) | P Value * |
| Age, years | 62 (18-91) | 59 (19-94) | 58 (33-88) | 61 (18-94) | 0.73 | 62 (18-91) | 60 (19-94) | 63 (30-88) | 61 (18-94) | 0.25 |
| Gender, % male | 66.4 | 63.2 | 64.3 | 65 | 0.90 | 68.5 | 59.5 | 70.4 | 65 | 0.38 |
| SAPS II | 48 (22-120) | 50 (15-96) | 44 (19-65) | 49 (15-120) | 0.58 | 49 (22-120) | 49 (15-96) | 45 (19-93) | 49 (15-120) | 0.44 |
| SOFA | 7 (2-15) | 7 (2-16) | 7 (1-11) | 7 (1-16) | 0.91 | 7 (2-15) | 7 (2-16) | 7 (1-16) | 7 (1-16) | 0.87 |
| Surgical, % | 21.2 | 26.3 | 28.6 | 23.6 | 0.65 | 22.8 | 25 | 22.2 | 23.6 | 0.93 |
| Sepsis origin, % | | | | | | | | | | |
| Lung | 56.7 | 47.4 | 64.3 | 53.7 | 0.36 | 54.3 | 50 | 59.3 | 53.7 | 0.67 |
| Abdomen | 20.4 | 21.1 | 21.4 | 20.7 | 0.99 | 20.7 | 22.6 | 14.8 | 20.7 | 0.68 |
| Urinary | 3.5 | 5.3 | 7.1 | 4.4 | 0.75 | 4.3 | 4.8 | 3.7 | 4.4 | 0.97 |
| Laboratory variables | | | | | | | | | | |
| Leucocyte count, x 10 ³ /mm ³ | 10.7 (0.1-55) | 12.3 (0.1-92.5) | 15.8 (1.8-32.7) | 11.4 (0.1-92.5) | 0.42 | 11.4 (0.1-55) | 12.4 (0.1-92.5) | 9.1 (0.4-32.7) | 11.4 (0.1-92.5) | 0.76 |
| Neutrophil count, x 10 ³ /mm ³ | 9.3 (0.1-46.2) | 10.4 (0.1-74.9) | 9.7 (1-28.4) | 9.1 (0.1-74.9) | 0.84 | 10.1 (0.1-46.2) | 10.4 (0.1-74.9) | 8.4 (0.5-29.3) | 9.1 (0.1-74.9) | 0.56 |
| Lymphocyte count, x 10 ³ /mm ³ | | 0.7 (0.1-3.7) | 1.7 (0.2-2.5) | 0.7 (0.1-11.9) | 0.005 | 0.7 (0.1-11.9) | 0.6 (0.1-5.8) | 0.9 (0.2-2.5) | 0.7 (0.1-11.9) | 0.17 |
| Monocyte count, x 10 ³ /mm ³ | 0.5 (0.1-2.9) | 0.6 (0.1-4.6) | 0.9 (0.1-7.9) | 0.6 (0.1-7.9) | 0.24 | 0.5 (0.1-2.7) | 0.6 (0.1-4.6) | 0.5 (0.1-7.9) | 0.6 (0.1-7.9) | 0.87 |

medRxiv preprint doi: https://doi.org/10.1101/2021.02.19.21252097; this version posted February 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 2.

Co-dominant model

| | | G-7 | 12A (rs12596 | 540) | | G-286A (rs3087456) | | | | | |
|-----------------------------|-----------------|----------------|----------------|---------------|--------------|--------------------|----------------|----------------|---------------|--------------|--|
| | AA (n = 113) | AG (n = 76) | GG (n = 14) | All (n = 203) | P Value * | AA (n = 92) | AG (n = 84) | GG (n = 27) | All (n = 203) | P Value * | |
| 28-d mortality, n (%) | 45 (39.8) | 24 (31.6) | 8 (57.1) | 77 (37.9) | 0.16 | 35 (38) | 27 (32.1) | 15 (55.6) | 77 (37.9) | 0.10 | |
| 7-d mortality, n (%) | 31 (27.2) | 18 (23.7) | 7 (50) | 56 (27.6) | 0.13 | 25 (27.2) | 21 (25) | 10 (37) | 56 (27.6) | 0.47 | |
| Secondary infections, n (%) | 23 (20.3) | 18 (23.7) | 2 (14.3) | 43 (21.2) | 0.70 | 19 (20.7) | 20 (23.8) | 4 (14.8) | 43 (21.2) | 0.61 | |

A-dominant model

| | | G-7 1 | 12A (rs12596 | 540) | G-286A (rs3087456) | | | | | |
|-----------------------------|-----------------------|----------------|--------------|-------------|--------------------|-----------------------|----------------|-------|-------------|--------------|
| | AA or AG (n = 189) | GG (n = 14) | OR | 95% CI | P Value * | AA or AG (n = 189) | GG (n = 27) | OR | 95% CI | P Value * |
| 28-d mortality, n (%) | 69 (36.5) | 8 (57.1) | 2.319 | 0.773-6.960 | 0.13 | 62 (35.2) | 15 (55.6) | 2.298 | 1.013-5.217 | 0.043 |
| 7-d mortality, n (%) | 49 (25.9) | 7 (50) | 2.857 | 0.954-8.558 | 0.05 | 46 (50) | 10 (37) | 1.662 | 0.710-3.891 | 0.24 |
| Secondary infections, n (%) | 41 (21.7) | 2 (14.3) | 0.602 | 0.129-2.796 | 0.49 | 39 (20.7) | 4 (14.8) | 0.611 | 0.199-1.872 | 0.38 |